CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
Recruiting · NCT07184775 · Interventional (participants receive a specific treatment) · Lead sponsor: Thomas Jefferson University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Who can take part
Inclusion criteria
- singleton pregnancies
- fetuses without anomalies
- diagnosis of Type 2 diabetes
- initiation of prenatal care at \<20 weeks gestation
Exclusion criteria
- diagnosis of Type 1 diabetes
- allergy to insulin
- inability to wear a continuous glucose monitor
Where it is running
2 locations listed across 2 US states.
- Jefferson Health New Jersey - Sewell, New Jersey, United States
- Thomas Jefferson University - Philadelphia, Pennsylvania, United States